R&D News | pharmaphorum

News

Sensorion files to start trials of deafness gene therapy

French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

FDA approves first progression-slowing Alzheimer's drug

Eisai's Leqembi, marketed by Biogen, secured full FDA regulatory approval as expected

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

News

Study shows psilocybin offers cost-effective solution for ma...

Psilocybin, a psychedelic compound found in certain mushrooms, could offer a more cost-effective treatment option for major depressive disorder than current methods, according to rese

Sensorion files to start trials of deafness gene therapy

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

FDA approves first progression-slowing Alzheimer's drug

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Study shows psilocybin offers cost-effective solution for ma...

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks